Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE)
收藏DataCite Commons2025-01-06 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006840/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Outcome Measures:
The primary endpoint was the time to onset of symptom relief of the first attack in the
double blind phase. H0: λ icatibant/λ tranexamic acid =1 versus H1: λ icatibant/λ tranexamic
acid ≠1 Where: λ icatibant refers to the hazard rate under icatibant and λ tranexamic acid
refers to the hazard rate under tranexamic acid.
Secondary Outcome Measures:
- Additional efficacy assessments (Time to Almost Complete Symptom Relief)
- Safety and tolerability
- Pharmacoeconomics
提供机构：
Vivli
创建时间：
2021-04-07
